483
BioEclipse Therapeutics, Inc.BioEclipse Therapeutics, Inc. – FDA 483, Mar 25, 2025
Record Details
An FDA inspection of BioEclipse Therapeutics, Inc. in Mountain View, CA, revealed a significant failure in the proper monitoring of a clinical study. The sponsor did not adequately conduct monitoring activities, including during an enrollment pause, which resulted in numerous unresolved protocol deviations and unmonitored adverse and serious adverse events. This indicates a serious lapse in ensuring study integrity and subject safety.
View Company Profile
ID · 15a9d628-2d6b-4389-b51e-8419da94fe40
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.